Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBT Margin (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed EBT Margin for 16 consecutive years, with 10.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 701531.0% year-over-year to 10.71%, compared with a TTM value of 23.37% through Dec 2025, up 2597881.0%, and an annual FY2025 reading of 6.21%, up 1725375.0% over the prior year.
  • EBT Margin was 10.71% for Q4 2025 at Arrowhead Pharmaceuticals, down from 14.08% in the prior quarter.
  • Across five years, EBT Margin topped out at 68.11% in Q1 2025 and bottomed at 7004.6% in Q4 2024.
  • Average EBT Margin over 5 years is 813.05%, with a median of 165.54% recorded in 2021.
  • The sharpest move saw EBT Margin plummeted -383881bps in 2023, then skyrocketed 701531bps in 2025.
  • Year by year, EBT Margin stood at 229.13% in 2021, then soared by 71bps to 66.82% in 2022, then tumbled by -5745bps to 3905.63% in 2023, then plummeted by -79bps to 7004.6% in 2024, then surged by 100bps to 10.71% in 2025.
  • Business Quant data shows EBT Margin for ARWR at 10.71% in Q4 2025, 14.08% in Q3 2025, and 644.97% in Q2 2025.